Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7243 results

Sort By:

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

Study ID: NCT06074666
Start Date: 2024-11-07
End Date: 2027-10-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

CareMeds Intervention

Usual Care Group

Sponsor

Roswell Park Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

Study ID: NCT04643366
Start Date: 2021-01-28
End Date: 2033-01-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

54

Intervention / Treatment

Chemotherapy

Radiation Therapy

Sponsor

Virginia Commonwealth University

Source: clinicaltrials.gov

Share:
Add to list

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Study ID: NCT05090566
Start Date: 2021-10-27
End Date: 2027-10-23
Study Type

Interventional

Study Phase

Phase2

No. of Participants

120

Intervention / Treatment

Aller

Elranatamab + lenalidomide + dexamethasone

Sponsor

Pfizer

Source: clinicaltrials.gov

Share:
Add to list

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Study ID: NCT04756726
Start Date: 2021-04-27
End Date: 2025-12-07
Study Type

Interventional

Study Phase

Phase2

No. of Participants

224

Intervention / Treatment

cemsidomide

Dexamethasone Oral

Sponsor

C4 Therapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Study ID: NCT05267626
Start Date: 2022-04-04
End Date: 2025-09-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

159

Intervention / Treatment

AU-007

Aldesleukin

Avelumab

Nivolumab

Sponsor

Aulos Bioscience, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Study ID: NCT03425526
Start Date: 2018-03-15
End Date: 2027-01-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

16

Intervention / Treatment

Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Resistance Exercise and Creatine in Colorectal Cancer

Study ID: NCT06420726
Start Date: 2024-01-09
End Date: 2025-07-22
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

40

Intervention / Treatment

Resistance Exercise

Sponsor

University of South Carolina

Source: clinicaltrials.gov

Share:
Add to list

PRE-I-SPY Phase I/Ib Oncology Platform Program

Study ID: NCT05868226
Start Date: 2023-02-15
End Date: 2029-12-30
Study Type

Interventional

Study Phase

Phase1

No. of Participants

124

Intervention / Treatment

ALX148

Fam-Trastuzumab Deruxtecan-Nxki

Zanidatamab

Tucatinib

Sponsor

QuantumLeap Healthcare Collaborative

Source: clinicaltrials.gov

Share:
Add to list

Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Study ID: NCT05573126
Start Date: 2023-01-11
End Date: 2026-11
Study Type

Interventional

Study Phase

Phase2

No. of Participants

60

Intervention / Treatment

Vosilasarm

Elaacestrant

Everolimus

Sponsor

Ellipses Pharma

Source: clinicaltrials.gov

Share:
Add to list

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

Study ID: NCT05183126
Start Date: 2022-03-28
End Date: 2025-12
Study Type

Interventional

Study Phase

Phase4

No. of Participants

22

Intervention / Treatment

Paclitaxel

Paclitaxel

Sponsor

University of Michigan Rogel Cancer Center

Source: clinicaltrials.gov

Share:
Add to list